Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

My Fellow Cellceutix Shareholders,

We are pleased to inform you that Cellceutix Chief Medical Officer Dr. Daniel Jorgensen is presenting this morning at an educational investor breakfast, "Understanding QIDP and Other 21st Century Incentives for Developing and Marketing Anti-Infective Medicines," being held at the Palace Hotel in New York City from 8:30 AM – 12:00 PM ET. This investor event is focused on the effect of the GAIN (Generating Antibiotic Incentives Now) Act, QIDP (Qualified Infectious Disease Product) designation and other efforts supporting development of anti-infective products.

Dr. Jorgensen will be speaking along with other scientists, legislators and industry executives. Dr. Jorgensen will be presenting during the portion of the meeting titled, “Current Anti-Infectives Products in Development” discussing Cellceutix’s novel class of antimicrobials called Host Defense Protein (HDP) mimetics, which includes Brilacidin, our lead HDP mimetic that recently completed a Phase 2 trial for the treatment of Acute Bacterial Skin and Skin Structure Infections. The PowerPoint presentation can be viewed on the Cellceutix website under the “Investors, Events and Presentations” tab (http://cellceutix.com/events/#sthash.QpoOxpUu.dpbs).

Interested parties may also view the event via a live webcast at: http://psav.rampard.com/20150521/reg.jsp. The event will also remain available following the live broadcast.


Sincerely,

The Cellceutix Team